MTOR and acute myeloid leukemia: Several studies have shown that autophagy can be activated after treatment with deoxycytidine analogues [88,206], BET inhibitors [217], mTOR catalytic inhibitors [87], histone methyltransferase inhibitors [218], and BCL2 inhibitors [109], actually contributing to the drug resistance of LSCs in AML.